Drug Class: Signaling Pathway Inhibitors

Integrin-FAK Inhibitors: FAK

Treatment given for recurrence occurring at any time after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

3 Prior Therapies 4 Prior Therapies

Integrin-FAK Inhibitors: FAK

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT01778803 I Defactinib, Paclitaxel A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer

Defactinib + weekly paclitaxel is well tolerated and showed promising activity

ORR: 18.2%
DCR: 63.6%

abs May 2014 and poster

NCT03875820 I Defactinib, VS-6766 FRAME: A Phase I Trial of the Combination of VS-6063 (FAK Inhibitor) and RO5126766 (CH5126776) (a Dual RAF/MEK Inhibitor) in Patients With Advanced Solid Tumours

VS-6766 (CH5127677)+defactinib shows promising clinical activity in patients with low grade serous ovarian cancer including those who have been previously treated with a MEK inhibitor

ORR: 46%
PFS: 23 months
11 KRAS MUT: ORR: 64%
9 KRAS WT: ORR: 44%

abs Apr 2021 and poster, abs Sep 2021

< Return to Drug Classes

< Return to Clinical Trial Results Homepage